Pegipanermin: meta-analysis of COVID-19 studies

All studies   Mortality   ICU   Hospitalization   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 77 patientsc19early.org

Pegipanermin for COVID-19

Serious outcome risk
Pegipanermin
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−290%
Mortality (1)−290%
ICU admission (1)−241%
Hospitalization (1)−38%
RCTs (1)−290%
Late (1)−290%
00.511.5+
← Pegipanermin
reduces riskIncreased
risk →
c19early.org
October 2026

Pegipanermin COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Tesi (DB RCT)−290%3.90 · 0.46–33.30death4/391/38
Late treatment−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.22
All studies−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2200.511.52+
Rotate screen for more detailsIncrease width for more details
← Pegipanermin
reduces riskPegipanermin
increases risk →
c19early.org
October 2026

Pegipanermin COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Tesi (DB RCT)−290%3.90 · 0.46–33.304/391/38
Late treatment−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.22
All studies−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2200.511.52+
Rotate screen for more detailsIncrease width for more details
← Pegipanermin
reduces riskPegipanermin
increases risk →
c19early.org
October 2026

Pegipanermin COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Tesi (DB RCT)−241%3.41 · 0.76–15.397/392/38
Late treatment−241%3.41 · 0.76–15.397/392/38241% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.11
All studies−241%3.41 · 0.76–15.397/392/38241% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1100.511.52+
Rotate screen for more detailsIncrease width for more details
← Pegipanermin
reduces riskPegipanermin
increases risk →
c19early.org
October 2026

Pegipanermin COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Tesi (DB RCT)−38%1.38 · 0.88–2.16hosp. time39 (n)38 (n)
Late treatment−38%1.38 · 0.88–2.1639 (n)38 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.16
All studies−38%1.38 · 0.88–2.1639 (n)38 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.1600.511.52+
Rotate screen for more detailsIncrease width for more details
← Pegipanermin
reduces riskPegipanermin
increases risk →
c19early.org
October 2026

Pegipanermin COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Tesi (DB RCT)−290%3.90 · 0.46–33.30death4/391/38
Late treatment−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.22
All studies−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2200.511.52+
Rotate screen for more detailsIncrease width for more details
← Pegipanermin
reduces riskPegipanermin
increases risk →
c19early.org
October 2026

Pegipanermin COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Tesi (DB RCT)−290%3.90 · 0.46–33.30death4/391/38
Late treatment−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.22
All studies−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2200.511.52+
Rotate screen for more detailsIncrease width for more details
← Pegipanermin
reduces riskPegipanermin
increases risk →
c19early.org
October 2026

Pegipanermin COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Tesi (DB RCT)−290%3.90 · 0.46–33.304/391/38
Late treatment−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.22
All studies−290%3.90 · 0.46–33.304/391/38290% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.2200.511.52+
Rotate screen for more detailsIncrease width for more details
← Pegipanermin
reduces riskPegipanermin
increases risk →